Skip to main content
Signal8

VACCINEX, INC. (VCNX)

Vaccinex, Inc. is a biotechnology firm operating in the clinical stage, dedicated to identifying and developing specialized biological therapies. Its core mission is to address serious medical conditions and diseases that currently lack adequate treatment options. The company's therapeutic endeavors encompass a broad spectrum of illnesses, including various forms of cancer, neurodegenerative disorders, and autoimmune diseases. At the forefront of its pipeline is pepinemab, a humanized monoclonal antibody. This leading candidate has either concluded or is scheduled for Phase 1b/2 clinical investigations, exploring its efficacy against non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. Furthermore, Vaccinex is progressing with VX5, a human antibody targeting CXCL13, which is presently in preclinical assessment for potential application in multiple sclerosis (MS) and other autoimmune conditions. The company was established in 2001 and has its principal operations located in Rochester, New York.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Vaccinex, Inc. logo

Vaccinex, Inc.

OTC:VCNXHealthcare
+0.00%$1.00
Mkt Cap$2.68M
EV-
Float1.02M
O/S2.68M
VOL2K sh
$ Vol$2K
RVOL1.69×
Inst Own-
Net Cash/Sh-
Dilution

VACCINEX, INC. (VCNX) dilution facts from SEC filings

Snapshot as of Dec 31, 2024, built from 46 SEC filings.

Shelf registration
None on file in the filings reviewed
At-the-market (ATM) program
No active program in the filings reviewed
Warrants outstanding
6 warrant series recorded as outstanding
Most recent offering
PIPE, closed Nov 14, 2024
Source: 10-K filed Apr 15, 2025

Check another stock for dilution

Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.

Unlock with Signal8 Pro